175 related articles for article (PubMed ID: 30146086)
21. The innovative therapies that could break the brain-cancer stalemate.
Willyard C
Nature; 2018 Sep; 561(7724):S59-S61. PubMed ID: 30258164
[No Abstract] [Full Text] [Related]
22. Bladder cancer in 2011: the dawn of personalized medicine.
Flaig TW; Theodorescu D
Nat Rev Urol; 2011 Dec; 9(2):65-6. PubMed ID: 22187014
[TBL] [Abstract][Full Text] [Related]
23. Adaptive treatments show promise in breast cancer.
Baker H
Lancet Oncol; 2016 Aug; 17(8):e327. PubMed ID: 27425815
[No Abstract] [Full Text] [Related]
24. Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments.
Galanis E; Wu W; Sarkaria J; Chang SM; Colman H; Sargent D; Reardon DA
Curr Oncol Rep; 2011 Feb; 13(1):42-9. PubMed ID: 21125354
[TBL] [Abstract][Full Text] [Related]
25. Achieving the goals of effective, safe, and individualized cancer care.
Roberts SA; Karnes EK; Allen JD; Benner JS; Sigal EV; McClellan M
Clin Cancer Res; 2011 Nov; 17(21):6632-3. PubMed ID: 22046023
[No Abstract] [Full Text] [Related]
26. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
[TBL] [Abstract][Full Text] [Related]
27. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
Albin N; Mc Leer A; Sakhri L
Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
[TBL] [Abstract][Full Text] [Related]
28. Facilitating access to new therapeutic options through clinical trials: the vision of a regulator to reconcile innovation and safety.
Vignot S; Martin M; Albin N; Schurtz C; Chapel E
Ann Oncol; 2019 Nov; 30(11):1694-1696. PubMed ID: 31501860
[No Abstract] [Full Text] [Related]
29. Precision medicine clinical trials: defining new treatment strategies.
Heckman-Stoddard BM; Smith JJ
Semin Oncol Nurs; 2014 May; 30(2):109-16. PubMed ID: 24794084
[TBL] [Abstract][Full Text] [Related]
30. [The breakthrough of personalized medicine, new hopes and new challenges].
Flippot R; Massard C; Auclin E; Azria D; Bourien H; Rochigneux P; Schernberg A; Verlingue L; Zafrani L; Vignot S
Bull Cancer; 2017 Sep; 104(9):735-743. PubMed ID: 28807365
[TBL] [Abstract][Full Text] [Related]
31. Current standards and new innovative approaches for treatment of pancreatic cancer.
Conroy T; Bachet JB; Ayav A; Huguet F; Lambert A; Caramella C; Maréchal R; Van Laethem JL; Ducreux M
Eur J Cancer; 2016 Apr; 57():10-22. PubMed ID: 26851397
[TBL] [Abstract][Full Text] [Related]
32. Multistage adaptive biomarker-directed targeted design for randomized clinical trials.
Gao Z; Roy A; Tan M
Contemp Clin Trials; 2015 May; 42():119-31. PubMed ID: 25778672
[TBL] [Abstract][Full Text] [Related]
33. Novel clinical trial designs for innovative therapies.
Schellens JH; Beijnen JH
Clin Pharmacol Ther; 2009 Feb; 85(2):212-6. PubMed ID: 19109591
[No Abstract] [Full Text] [Related]
34. Group sequential designs for developing and testing biomarker-guided personalized therapies in comparative effectiveness research.
Lai TL; Liao OY; Kim DW
Contemp Clin Trials; 2013 Nov; 36(2):651-63. PubMed ID: 23994669
[TBL] [Abstract][Full Text] [Related]
35. Design and conduct of early clinical studies of two or more targeted anticancer therapies: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.
Seymour LK; Calvert AH; Lobbezoo MW; Eisenhauer EA; Giaccone G;
Eur J Cancer; 2013 May; 49(8):1808-14. PubMed ID: 23428669
[TBL] [Abstract][Full Text] [Related]
36. Early phase trial designs and endpoints for targeted therapies in rare genotype subsets.
Mandrekar SJ
Am Soc Clin Oncol Educ Book; 2014; ():e107-10. PubMed ID: 24857087
[TBL] [Abstract][Full Text] [Related]
37. Targeted therapy in cancer.
Tsimberidou AM
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1113-32. PubMed ID: 26391154
[TBL] [Abstract][Full Text] [Related]
38. Introduction: Personalized medicine: what is it and what are the challenges?
Sigman M
Fertil Steril; 2018 Jun; 109(6):944-945. PubMed ID: 29935651
[TBL] [Abstract][Full Text] [Related]
39. Optimal Bayesian adaptive trials when treatment efficacy depends on biomarkers.
Zhang Y; Trippa L; Parmigiani G
Biometrics; 2016 Jun; 72(2):414-21. PubMed ID: 26575199
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
